March 4, 2021 10:51 AM EST

Pfizer's Xalkori follow-up, which smoked the older drug in 1st-line patients, scores double win at the FDA

Nicole DeFeudis

Editor

Despite being the first to market in ALK-positive non-small cell lung cancer, Pfizer’s Xalkori languished on the shelf as other competitors outpaced it. Now, after …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer's Xalkori follow-up, which smoked the older drug in 1st-line patients, scores double win at the FDA

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Pfiz­er's Xalko­ri fol­low-up, which smoked the old­er drug in 1st-line pa­tients, scores dou­ble win at the FDA

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Pfizer's Xalkori follow-up, which smoked the older drug in 1st-line patients, scores double win at the FDA